Takeda

News

Takeda to partner on patient-centric data with Seqster

Takeda has partnered with patient data firm Seqster in a drive to improve care through better access and understanding of patient-level data.

News

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

NHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it the first and only medicine backed for what is the most common inher

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files Darzalex Faspro for rare disease light chain a...

Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease light chain (AL) amyloidosis.

News

A healthy discussion on funding tomorrow’s treatments

Despite biosims, ulcerative colitis drugs still cost too muc...

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review

News

Takeda agrees $2.3bn sale of Japanese consumer health unit

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs.

News

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.

Takeda to partner on patient-centric data with Seqster

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

Janssen files Darzalex Faspro for rare disease light chain a...

Despite biosims, ulcerative colitis drugs still cost too muc...

Takeda agrees $2.3bn sale of Japanese consumer health unit

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks